Varicose Vein Ablation — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p><strong>Varicose vein ablation</strong> refers to a group of minimally invasive, catheter-based or injection-based techniques used to close and eliminate incompetent superficial veins — most commonly the <strong>Great Saphenous Vein (GSV)</strong> and <strong>Small Saphenous Vein (SSV)</strong> — that are the source of varicose veins in the leg. By destroying the internal lining (endothelium) of the defective vein and causing it to fibrose and be reabsorbed by the body, ablation eliminates reflux (backward blood flow) and removes the hydrostatic pressure that causes the tortuous, bulging superficial veins visible under the skin.</p><p>Varicose veins affect an estimated 23–35% of the adult population in Western countries and are caused by dysfunction of the venous one-way valve system that prevents blood from flowing backwards against gravity. When these valves fail, blood pools in the superficial veins, causing progressive venous hypertension that leads to vein wall dilation, tortuosity, and the entire spectrum of chronic venous disease — from cosmetically unacceptable dilated veins to painful, swollen legs, skin changes (lipodermatosclerosis, haemosiderosis), and ultimately, chronic venous ulceration.</p><p>Ablation procedures have largely replaced open surgical stripping of varicose veins in most developed-world vascular surgery and interventional radiology centres. They are performed under local (tumescent) anaesthesia as outpatient procedures, carry a very low complication rate, and produce durable results with high patient satisfaction. The most established techniques are:</p><ul><li><strong>Endovenous Laser Ablation (EVLA / EVLT):</strong> Uses laser energy delivered via an intraluminal fibre to thermally destroy the vein wall</li><li><strong>Radiofrequency Ablation (RFA / ClosureFast):</strong> Uses radiofrequency electrical energy via a segmental heating catheter</li><li><strong>Ultrasound-guided Foam Sclerotherapy (UGFS):</strong> Uses an injected chemical foam to damage the vein endothelium</li><li><strong>Mechanochemical Ablation (MOCA / ClariVein):</strong> Combines mechanical vein wall injury with liquid sclerosant injection</li><li><strong>Cyanoacrylate Glue Ablation (VenaSeal):</strong> Seals the vein with medical-grade cyanoacrylate adhesive</li></ul><p>All ablation procedures are performed under continuous ultrasound guidance (duplex scanning) to identify target veins, guide catheter placement, and confirm occlusion after treatment.</p>

<p>Varicose vein ablation treats venous disease across the full CEAP (Clinical–Aetiological–Anatomical–Pathophysiological) classification spectrum:</p><ul><li><strong>Primary varicose veins (CEAP C2):</strong> The most common indication. Tortuous, bulging superficial veins >3mm in diameter with documented saphenofemoral or saphenopopliteal junction incompetence on duplex ultrasound. Symptoms include aching, heaviness, throbbing, itching, and leg fatigue that worsen with prolonged standing.</li><li><strong>Oedema of venous origin (CEAP C3):</strong> Dependent ankle and lower leg oedema that improves with elevation, associated with superficial venous incompetence. Ablation of the incompetent truncal vein significantly reduces chronic oedema in many patients.</li><li><strong>Skin changes — lipodermatosclerosis and haemosiderin deposition (CEAP C4):</strong> Venous hypertension causes inflammatory skin changes including hardening (lipodermatosclerosis), brown discolouration from haemosiderin, varicose eczema (stasis dermatitis), and corona phlebectatica (fan-like small veins around the ankle). Ablation reduces venous pressure and can stabilise or reverse these changes.</li><li><strong>Healed venous ulcer (CEAP C5) and active venous ulcer (CEAP C6):</strong> Venous leg ulcers — the most severe consequence of chronic venous disease — benefit from early intervention to reduce venous hypertension. The EVRA (Early Venous Reflux Ablation) trial (2018, published in NEJM) conclusively demonstrated that early superficial vein ablation accelerates ulcer healing and reduces recurrence compared to compression-only therapy.</li><li><strong>Great Saphenous Vein (GSV) reflux:</strong> The most commonly treated vessel. GSV incompetence from the saphenofemoral junction (SFJ) at the groin is the aetiology in approximately 80% of primary varicose vein presentations.</li><li><strong>Small Saphenous Vein (SSV) reflux:</strong> SSV incompetence from the saphenopopliteal junction (SPJ) at the back of the knee accounts for approximately 15–20% of varicose vein cases.</li><li><strong>Recurrent varicose veins after previous surgery:</strong> Endovenous ablation is technically feasible and effective for recurrent varicose veins after previous high ligation and stripping, phlebectomy, or sclerotherapy.</li></ul>

<p>Patient selection is guided by duplex ultrasound findings, symptom burden, and clinical examination. The following criteria define eligibility:</p><p><strong>Suitable candidates:</strong></p><ul><li>Adults with symptomatic varicose veins (CEAP C2 and above) confirmed on clinical examination</li><li>Documented truncal venous incompetence (GSV, SSV, or both) on duplex ultrasound — specifically, reflux duration >0.5 seconds in the superficial system is the diagnostic threshold in most guidelines</li><li>Patients who have failed or are unable to tolerate conservative management (graduated compression stockings) or who have significant symptom burden impacting quality of life</li><li>All CEAP classes C2–C6, with higher-grade disease (C4–C6) requiring more urgent intervention</li><li>Adequate vein diameter — most ablation techniques work best for veins 3–10mm in diameter; very large or tortuous veins (>12mm) may be better treated with foam sclerotherapy or phlebectomy</li><li>Ability to wear compression stockings post-procedure and walk immediately after the procedure</li></ul><p><strong>Relative contraindications (requiring specialist assessment):</strong></p><ul><li><strong>Pregnancy:</strong> Elective ablation is deferred until 3–6 months after delivery, as post-partum hormonal changes often lead to spontaneous improvement. Emergency treatment for thrombophlebitis during pregnancy is assessed individually.</li><li><strong>Immobility:</strong> The ability to walk immediately post-procedure is important to prevent deep vein thrombosis (DVT). Patients with significant mobility restrictions require individual risk-benefit assessment.</li><li><strong>Known thrombophilia or active malignancy:</strong> Patients at high DVT risk require haematology input and chemical DVT prophylaxis.</li><li><strong>Arterial disease (ABPI <0.5):</strong> Compression stockings must be used with caution in the presence of significant peripheral arterial disease. Arterial assessment (ABPI measurement) is performed before prescribing compression.</li><li><strong>History of allergy to cyanoacrylate:</strong> Absolute contraindication to VenaSeal glue ablation. An allergy patch test or history review is performed before VenaSeal use.</li></ul><p><strong>Investigation requirements before ablation:</strong> All patients must have a standing duplex ultrasound scan of both legs performed by a trained vascular sonographer to map the anatomy of incompetent veins and exclude coexisting deep vein disease before planning ablation.</p>

<p>The choice of ablation technique depends on vein anatomy, diameter, tortuosity, depth, local expertise, and patient preference. All techniques are performed under duplex ultrasound guidance:</p><p><strong>1. Endovenous Laser Ablation (EVLA / EVLT)</strong><br>Under tumescent local anaesthesia (dilute lidocaine with adrenaline injected around the entire length of the target vein under ultrasound), a laser fibre is introduced into the vein via a small puncture and positioned below the SFJ. Laser energy (810nm, 980nm, 1320nm, or 1470nm wavelength) is delivered continuously or in pulses as the fibre is slowly withdrawn, thermally damaging the vein wall and inducing fibrosis. The procedure takes 30–60 minutes. Closure rates at 5 years: 90–95%. NICE-recommended first-line treatment in the UK.</p><p><strong>2. Radiofrequency Ablation (RFA — ClosureFast / ClosureFAST)</strong><br>A segmental radiofrequency catheter (ClosureFast, Medtronic) is introduced into the target vein via tumescent anaesthesia. The catheter heats 7cm vein segments to 120°C for 20 seconds per segment, causing immediate endothelial destruction and collagen contraction. The catheter is then repositioned and the next segment treated until the entire refluxing length is ablated. RFA produces less perioperative pain and bruising than early-generation EVLA and is frequently preferred for patient comfort. Closure rates equivalent to EVLA at 5 years.</p><p><strong>3. Ultrasound-Guided Foam Sclerotherapy (UGFS)</strong><br>A chemical sclerosant (sodium tetradecyl sulphate 3%, or polidocanol 2–3%) is mixed with air or CO2 using the Tessari method to create a microfoam. The foam is injected directly into the target vein under ultrasound guidance, displacing blood and causing endothelial chemical injury and subsequent thrombosis and fibrosis. UGFS is particularly valuable for recurrent veins, varicosities unsuitable for thermal ablation (tortuous segments, very large veins), and as an adjunct treatment for residual tributaries. Does not require anaesthesia. Multiple sessions may be needed. 5-year closure rates: 70–85% (lower than thermal ablation).</p><p><strong>4. Mechanochemical Ablation (MOCA — ClariVein)</strong><br>The ClariVein catheter uses a rotating wire tip to mechanically abrade the vein endothelium simultaneously with injection of liquid sclerosant. No tumescent anaesthesia is needed, making it truly anaesthesia-free. Good patient tolerability and closure rates of 85–90% at 2 years. Particularly useful for patients who wish to avoid injections for tumescent anaesthesia.</p><p><strong>5. Cyanoacrylate Glue Ablation (VenaSeal)</strong><br>Medical-grade n-butyl cyanoacrylate (tissue glue) is injected in precise aliquots along the target vein under duplex guidance, sealing the vein mechanically without thermal or chemical endothelial destruction. Requires no tumescent anaesthesia (a single local anaesthetic injection at entry point only) and no post-procedure compression stockings in many centres. Closure rates 95% at 3 years. Higher cost due to device expense; rare hypersensitivity reactions to cyanoacrylate reported.</p><p><strong>6. Ambulatory Phlebectomy (adjunctive):</strong> Removal of residual tributary varicosities through multiple 1–2mm skin punctures under local anaesthesia on the same day as trunk ablation or at a separate session.</p>

<p>Endovenous ablation techniques offer substantial advantages over traditional surgical stripping and non-treatment:</p><ul><li><strong>Symptom relief:</strong> 85–95% of patients report significant reduction in leg aching, heaviness, throbbing, itching, and fatigue after successful ablation. Symptom improvement is often rapid, becoming apparent within days to weeks of treatment.</li><li><strong>High anatomical success rates:</strong> EVLA and RFA achieve 5-year GSV occlusion rates of 90–95%, substantially superior to compression-only therapy and comparable to or superior to surgical stripping in randomised trials.</li><li><strong>Minimally invasive — no general anaesthesia:</strong> All thermal ablation techniques are performed under local tumescent anaesthesia. Patients walk to their car after the procedure and return home. Hospital admission is not required.</li><li><strong>Rapid recovery:</strong> Most patients return to light activities the same day, desk work within 1–2 days, and normal activities within 1–2 weeks — dramatically faster than the 4–6 week recovery from open surgical stripping.</li><li><strong>Cosmetic improvement:</strong> Elimination of the feeder truncal vein causes many tributary varicosities to shrink and disappear over 3–6 months. Residual varicosities can be treated by phlebectomy or foam sclerotherapy.</li><li><strong>Ulcer healing:</strong> The EVRA trial (NEJM, 2018) demonstrated that early ablation halves the time to venous ulcer healing compared to compression-only therapy and reduces 24-week ulcer recurrence rates.</li><li><strong>Prevention of disease progression:</strong> Untreated venous incompetence is a progressive condition; ablation prevents deterioration from CEAP C2 to C4–C6 (skin changes and ulceration) in many patients.</li><li><strong>No visible scar:</strong> A single small puncture site is used for catheter entry; no incision comparable to surgical stripping is required.</li></ul>

<p>Varicose vein ablation is a low-risk procedure with a favourable safety profile. Patients should nonetheless be counselled about the following potential complications:</p><ul><li><strong>Bruising and tenderness:</strong> Very common (up to 50%) — particularly along the ablated vein track, due to tumescent injection and thermal injury to the vein. Resolves within 1–4 weeks. More pronounced with EVLA than RFA in studies.</li><li><strong>Thrombophlebitis (superficial vein thrombosis):</strong> Inflammation and thrombosis of treated veins causes localised hardness, redness, and tenderness along the vein track in 2–5% of patients. Managed with anti-inflammatory drugs (ibuprofen) and compression.</li><li><strong>Deep Vein Thrombosis (DVT):</strong> Thermal endovenous heat-induced thrombosis (EHIT) — extension of the ablation thrombus from the superficial into the deep venous system — occurs in 0.5–1.5% of procedures. Most are minor (EHIT Class 1–2) and resolve spontaneously. EHIT Class 3–4 (significant deep vein extension) requires anticoagulation. Pulmonary embolism is very rare (<0.1%).</li><li><strong>Skin burns or paraesthesia:</strong> Inadequate tumescent anaesthesia can allow thermal injury to reach the skin surface or peri-vascular nerves, causing small skin burns or areas of numbness. Careful technique and adequate tumescent volumes virtually eliminate this risk.</li><li><strong>Nerve injury:</strong> The sural nerve (near the SSV) and saphenous nerve (near the below-knee GSV) are at risk of thermal or mechanical injury during ablation, causing temporary or rarely permanent numbness, tingling, or burning sensations in the calf or medial lower leg.</li><li><strong>Recanalisation:</strong> Partial or complete re-opening of the ablated vein occurs in 5–10% of cases over 5 years, potentially requiring re-treatment. Higher recanalisation rates are seen with foam sclerotherapy than with thermal ablation.</li><li><strong>Cyanoacrylate hypersensitivity (VenaSeal specific):</strong> Localised inflammatory skin reaction over the treated vein has been reported in 2–4% of patients receiving VenaSeal glue; systemic hypersensitivity is rare.</li><li><strong>Foam embolism (UGFS specific):</strong> Visual disturbances, transient neurological symptoms, and very rarely stroke have been reported after foam sclerotherapy, attributed to passage of foam through a patent foramen ovale (PFO). This complication is rare but highlights the need for careful patient selection for foam sclerotherapy.</li></ul>

<p>Recovery from varicose vein ablation is one of the fastest of any vascular procedure. The following post-procedure care is standard:</p><p><strong>Immediately after the procedure:</strong></p><ul><li>Compression bandage applied from foot to groin at the end of the procedure; replaced with class 2 compression stockings within 24 hours</li><li>Walking encouraged immediately — a 30-minute brisk walk post-procedure reduces DVT risk and enhances vein spasm</li><li>Driving is safe the same day for most patients (unless operated on the right leg with manual transmission)</li><li>Regular paracetamol and ibuprofen for the first 5–7 days to manage tenderness and thrombophlebitis</li></ul><p><strong>First 2 weeks:</strong></p><ul><li>Compression stockings worn continuously during waking hours for 7–14 days (protocol varies by centre and technique; VenaSeal may not require compression)</li><li>Avoid prolonged sitting or standing; take regular short walks of 5–10 minutes every 1–2 hours</li><li>Avoid heavy impact exercise (running, gym) for 1–2 weeks</li><li>Avoid hot baths, jacuzzi, and saunas for 2 weeks</li><li>Swimming is typically permitted at 2 weeks once puncture sites have healed</li></ul><p><strong>Follow-up duplex ultrasound:</strong></p><ul><li>A duplex scan at 2–7 days post-procedure confirms vein closure and screens for EHIT (endovenous heat-induced thrombosis extending into the deep system). This is standard practice in most published protocols.</li><li>Review at 6 weeks to assess residual varicosities for phlebectomy or foam sclerotherapy, and to plan further treatment sessions if needed</li><li>Annual clinical review for 2–3 years is recommended to detect late recanalisation and new incompetent tributaries</li></ul><p><strong>DVT prophylaxis:</strong></p><ul><li>Low-molecular-weight heparin (LMWH) is prescribed for high-risk patients (history of DVT, thrombophilia, BMI >30, immobility). Routine LMWH for all patients is not recommended by NICE but is used in higher-risk scenarios.</li></ul>

<p>The cost of varicose vein ablation varies significantly by country, healthcare system, technique, and whether one or both legs are treated:</p><ul><li><strong>United Kingdom (NHS):</strong> Available for symptomatic varicose veins (CEAP C2 with documented functional impairment, and C4–C6) via NHS referral under NICE guideline NG168. No patient cost for eligible patients. Private treatment: £1,500–£5,000 per leg depending on technique and extent.</li><li><strong>United States:</strong> $2,000–$7,000 per leg. Insurance coverage varies — many insurers cover thermal ablation for medically documented symptomatic C2–C6 disease with documented duplex findings and failed conservative treatment (3 months of compression stockings). Cosmetic-only claims are not covered.</li><li><strong>India:</strong> INR 40,000–1,20,000 per leg at reputable private vascular surgery or interventional radiology centres. Laser (EVLA) is widely available at top-tier hospitals in major cities.</li><li><strong>Thailand:</strong> USD 1,500–4,000 per leg at JCI-accredited hospitals. Thailand is a popular destination for varicose vein ablation medical tourism.</li><li><strong>Germany and Western Europe:</strong> EUR 1,500–4,000 per leg at private vascular clinics.</li><li><strong>Turkey:</strong> USD 1,000–3,000 per leg; growing interventional radiology sector with competitive pricing.</li></ul><p><strong>Factors that affect cost:</strong></p><ul><li>Technique used — VenaSeal and MOCA devices have higher consumable costs than EVLA or foam</li><li>Number of veins treated (GSV only vs. GSV + SSV + tributaries)</li><li>One leg vs. bilateral treatment</li><li>Whether adjunctive phlebectomy or foam sclerotherapy is needed for tributary veins</li><li>Pre-treatment duplex ultrasound mapping</li><li>Post-procedure duplex scan</li><li>Compression stockings (provided or self-purchased)</li><li>Surgeon / interventional radiologist experience and centre prestige</li></ul>

<p>Several alternatives to endovenous ablation exist, ranging from conservative measures to traditional open surgery:</p><ul><li><strong>Graduated compression stockings (conservative management):</strong> Class 2 (23–32 mmHg) or Class 3 (34–46 mmHg) compression hosiery is the cornerstone of conservative management. Compression reduces ambulatory venous pressure, relieves symptoms (aching, swelling, fatigue), and slows disease progression. It is the first-line treatment for most patients, recommended by NICE for at least 3 months before elective ablation is considered for non-ulcerating disease. However, it does not reverse the underlying venous incompetence and symptoms typically recur when stockings are removed.</li><li><strong>Conventional surgical stripping (high ligation and stripping):</strong> The traditional operation — division of the saphenofemoral or saphenopopliteal junction and stripping of the incompetent trunk under general or spinal anaesthesia — remains available and appropriate for certain presentations (very large veins, complex recurrent disease, veins unsuitable for catheter access). It requires general anaesthesia, a 1–2 day hospital stay, and 2–4 week recovery, with higher short-term complication rates than endovenous techniques. Long-term recurrence rates are similar to those of thermal ablation at 5 years.</li><li><strong>Ambulatory phlebectomy (alone):</strong> Removal of visible tributary varicosities through tiny skin punctures under local anaesthesia, without addressing the underlying truncal incompetence. Effective for removing cosmetically bothersome tributary veins but results in early recurrence as the feeding incompetent trunk remains. Usually combined with or following trunk ablation.</li><li><strong>Liquid sclerotherapy:</strong> Direct injection of liquid sclerosant into smaller reticular veins and telangiectasias (thread veins). Not suitable for large saphenous trunks but highly effective for small superficial cosmetic veins and small residual varicosities after trunk ablation.</li><li><strong>Lifestyle modification:</strong> Regular exercise (particularly walking and cycling), weight loss, leg elevation at rest, and avoidance of prolonged standing reduce symptom severity and slow disease progression. These are important adjuncts to any treatment strategy.</li><li><strong>Watchful waiting:</strong> For patients with mild, minimally symptomatic C2 disease and no skin changes, watchful waiting with compression stockings and lifestyle advice is appropriate. Treatment is escalated if symptoms worsen or complications arise.</li></ul><p>NICE guideline NG168 (2020) recommends endovenous thermal ablation (EVLA or RFA) as the preferred first-line interventional treatment for confirmed GSV incompetence, with UGFS or phlebectomy as appropriate alternatives when thermal ablation is not suitable.</p>